PE20110208A1 - Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno - Google Patents

Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno

Info

Publication number
PE20110208A1
PE20110208A1 PE2011000041A PE2011000041A PE20110208A1 PE 20110208 A1 PE20110208 A1 PE 20110208A1 PE 2011000041 A PE2011000041 A PE 2011000041A PE 2011000041 A PE2011000041 A PE 2011000041A PE 20110208 A1 PE20110208 A1 PE 20110208A1
Authority
PE
Peru
Prior art keywords
aza
oxa
dihydro
compounds
indacen
Prior art date
Application number
PE2011000041A
Other languages
English (en)
Inventor
Jose L Falco
Albert Palomer
Antonio Guglietta
Original Assignee
Ferrer Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41138660&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20110208(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int filed Critical Ferrer Int
Publication of PE20110208A1 publication Critical patent/PE20110208A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE 1,6-DIHIDRO-2H-3-OXA-6-AZA-as-INDACENO DE FORMULA (I) DONDE R1 ES H, ALQUILO(C1-C6) O CICLOALQUILO(C3-C6); R2 ES H, HALOGENO SELECCIONADO ENTRE CLORO Y BROMO, FENILO, COOH, ENTRE OTROS; R3 ES H, ALQUILO(C1-C6) O CICLOALQUILO(C3-C6); R4 ES ALQUILO(C1-C6), CICLOALQUILO(C3-C6), CHFCH3, OH, ENTRE OTROS; X ES HALOGENO SELECCIONADO ENTRE FLUORO Y CLORO. SON COMPUESTOS PREFERIDOS: N-[2-(4-FLUORO-1,6-DIHIDRO-2H-3-OXA-6-AZA-as-INDACEN-8-IL)-ETIL]-ACETAMIDA, N-[2-(4-FLUORO-1,6-DIHIDRO-2H-3-OXA-6-AZA-as-INDACEN-8-IL)-ETIL]-PROPIONAMIDA, N-[2-(4-FLUORO-1,6-DIHIDRO-2H-3-OXA-6-AZA-as-INDACEN-8-IL)-ETIL]-BUTIRAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DE LOS RECEPTORES DE MELATONINA SIENDO UTILES EN EL TRATAMIENTO DE LA DEPRESION, ANSIEDAD, INSOMNIO, ESQUIZOFRENIA
PE2011000041A 2008-07-30 2009-07-29 Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno PE20110208A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161485 2008-07-30

Publications (1)

Publication Number Publication Date
PE20110208A1 true PE20110208A1 (es) 2011-03-28

Family

ID=41138660

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000041A PE20110208A1 (es) 2008-07-30 2009-07-29 Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno

Country Status (16)

Country Link
US (1) US8227501B2 (es)
EP (1) EP2350088A1 (es)
JP (1) JP2011529477A (es)
KR (1) KR20110041495A (es)
CN (1) CN102112480A (es)
AR (1) AR075262A1 (es)
AU (1) AU2009275918A1 (es)
BR (1) BRPI0916395A2 (es)
CA (1) CA2731405A1 (es)
CL (1) CL2011000184A1 (es)
MX (1) MX2011001062A (es)
PE (1) PE20110208A1 (es)
RU (1) RU2011107443A (es)
TW (1) TW201018695A (es)
UY (1) UY32016A (es)
WO (1) WO2010012789A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103601683B (zh) * 2010-04-16 2016-03-30 中国科学院上海药物研究所 苯并杂环类化合物及其制备方法和用途
AR091699A1 (es) * 2012-07-10 2015-02-25 Astellas Pharma Inc Derivado de indol carboxamida
CN104109143B (zh) * 2013-04-22 2018-04-27 上海阳帆医药科技有限公司 一类褪黑激素(mt1-mt2)受体激动剂及其制备方法与用途
CN104326916B (zh) * 2014-10-10 2017-09-22 青岛农业大学 2‑氟‑4‑烯丙基‑6‑硝基苯酚与2‑氟‑4‑硝基‑6‑烯丙基苯酚的联合制备及用途
AU2017285813B2 (en) * 2016-06-17 2020-02-06 Daewoong Pharmaceutical Co., Ltd. Method for producing diphenylmethane derivative
KR20240044190A (ko) * 2022-09-28 2024-04-04 주식회사 대웅제약 이나보글리플로진의 신규한 결정형 및 이의 제조방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
WO1989001472A1 (en) 1987-08-17 1989-02-23 Nelson Research & Development Co. Melatonin analogues
FR2680366B1 (fr) * 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9326192D0 (en) * 1993-12-22 1994-02-23 Glaxo Group Ltd Chemical compounds
AU6241796A (en) * 1995-06-27 1997-01-30 Takeda Chemical Industries Ltd. 4-acylamino(halogeno) alkyl-quinoline derivatives, their preparation and their use as melatonin agonists
US5732360A (en) 1995-09-08 1998-03-24 At & T Wireless Services And Atmel Corp Mobile telecommunication device and method used for changing wireless communication between base stations of different kinds
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
CN100443480C (zh) * 1996-03-08 2008-12-17 武田药品工业株式会社 三环化合物及其制备和用途
FR2771739B1 (fr) * 1997-11-28 2001-04-20 Adir Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2784375B1 (fr) * 1998-10-12 2000-11-24 Adir Nouveaux derives cycliques a chaine cycloalkylenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2793793B1 (fr) * 1999-05-19 2004-02-27 Adir Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP1214944B1 (en) * 1999-08-20 2009-09-23 Takeda Pharmaceutical Company Limited Composition for PERCUTANEOUS ABSORPTION with a compound having a melatonin receptor agonist activity
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6737431B2 (en) * 2002-03-12 2004-05-18 Bristol-Myers Squibb Company Benzoxazole derivatives as novel melatonergic agents
DK1537113T5 (da) * 2002-06-21 2011-01-10 Suven Life Sciences Ltd Arylalkylindoler med serotoninreceptoraffinitet anvendelige som terapeutiske midler, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
US6908931B2 (en) * 2003-04-10 2005-06-21 Bristol-Myers Squibb Company Tetrahydroisoquinoline derivatives as melatonin MT2 antagonists
CA2551117A1 (en) 2003-12-23 2005-07-14 Abraxis Bioscience, Inc. Substituted melatonin derivatives, process for their preparation, and methods of use

Also Published As

Publication number Publication date
RU2011107443A (ru) 2012-09-10
BRPI0916395A2 (pt) 2016-02-16
CL2011000184A1 (es) 2011-09-16
MX2011001062A (es) 2011-03-24
JP2011529477A (ja) 2011-12-08
KR20110041495A (ko) 2011-04-21
CN102112480A (zh) 2011-06-29
AU2009275918A1 (en) 2010-02-04
UY32016A (es) 2010-01-29
TW201018695A (en) 2010-05-16
US20110144178A1 (en) 2011-06-16
WO2010012789A1 (en) 2010-02-04
CA2731405A1 (en) 2010-02-04
EP2350088A1 (en) 2011-08-03
AR075262A1 (es) 2011-03-23
US8227501B2 (en) 2012-07-24

Similar Documents

Publication Publication Date Title
PE20110208A1 (es) Compuestos de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno
PE20061298A1 (es) Compuestos derivados de dihidrobenzofurano como agonistas del receptor de serotonina 5-ht2c
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20091623A1 (es) DERIVADOS DE 1H-PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE RAF QUINASA
PE20061150A1 (es) Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1)
PE20071254A1 (es) Derivados de sulfonamidas como agentes moduladores de los receptores de orexina y su preparacion
PE20090892A1 (es) MODULADORES DUALES DE LOS RECEPTORES 5-HT2a Y D3
PE20061348A1 (es) DERIVADOS DEL ACIDO PIRMIDINCARBOXILICO COMO MODULADORES DE PPAR-alfa
PE20061163A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos
AR066155A1 (es) Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia
EA200801001A1 (ru) Соединения, которые обладают активностью по отношению к рецепторам м, и их применения в медицине
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
AR063015A1 (es) Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer
PE20091901A1 (es) Activadores de glucoquinasa
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20060610A1 (es) Derivados tetraciclicos como moduladores de los receptores de estrogeno
PE20091431A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
PE20061038A1 (es) Derivados del 1,5-difenil-1h-pirazol-3-il) oxadiazol como agentes antagonistas cb1 y su preparacion
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20110703A1 (es) Acidos naftilaceticos
PE20090655A1 (es) Derivados de 2-aza-biciclo[2.2.2]octano para prevencion o tratamiento de psicosis
PE20081851A1 (es) Derivados de espiropiperidina-glicinamida
AR074353A1 (es) Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica.
CL2012000516A1 (es) Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed